Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

• Yu-Ying Shi,
• Gang Fan,
• Ruirong Tan,
• Shan Li,
• Hua-Bing Sun,
• Rui Li,
• Mengni Yang,
• Shanshan Gao,
• Miao Liu,
• Meng-Yuan Dai

Affiliations

Yu-Ying Shi

Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University

Gang Fan

Department of Urology, Huazhong University of Science and Technology Union Shenzhen Hospital

Ruirong Tan

China Translational Chinese Medicine Key Laboratory of Sichuan Province, State Key Laboratory of Quality Evaluation of Traditional Chinese Medicine, Sichuan Institute for Translational Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences

Shan Li

Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University

Hua-Bing Sun

Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin Medical University

Rui Li

Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center

Mengni Yang

China Translational Chinese Medicine Key Laboratory of Sichuan Province, State Key Laboratory of Quality Evaluation of Traditional Chinese Medicine, Sichuan Institute for Translational Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences

Shanshan Gao

Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa

Miao Liu

Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School

Meng-Yuan Dai

Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University